Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1881 | Icosapent ethyl (IPE) Wiki | 1.00 |
| drug1291 | DynamX Bioadaptor Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003324 | Coronary Artery Disease NIH | 0.33 |
| D006331 | Heart Diseases NIH | 0.27 |
| D009203 | Myocardial Ischemia NIH | 0.22 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001677 | Coronary artery atherosclerosis HPO | 0.33 |
| HP:0001658 | Myocardial infarction HPO | 0.22 |
Navigate: Correlations HPO
There is one clinical trial.
The Infinity-Swedeheart trial is a prospective, multicenter, single-blind, randomized registry-based clinical trial. Eligible patients will be randomized 1:1 (DynamX Bioadaptor : Resolute Onyx).
Description: Device Oriented Clinical Endpoint (DOCE) of target lesion failure (TLF; cardiovascular death, target vessel myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (ID-TLR))
Measure: Target Lesion Failure (TLF) Time: 1 yearDescription: Lesion-Level Analysis
Measure: Device Success Time: During Study ProcedureDescription: Patient-Level Analysis
Measure: Procedural Success Time: In-Hospital, assessed up to 7 daysDescription: Composite Device Oriented Clinical Endpoint (DOCE) (TLF; cardiovascular death, TV-MI, ischemia-driven TLR)
Measure: Composite Rate of Device Oriented Clinical Endpoint (DOCE) Time: 30 days, 6 months, 1-5 yearsDescription: Composite Patient Oriented Clinical Endpoint (POCE) (all-cause mortality, any stroke, any myocardial infarction (includes non-target vessel territory) and any revascularization). Note: Stroke to be collected and included in the POCE at 1 year and 5 years only.
Measure: Composite Rate of Patient Oriented Clinical Endpoint (POCE) Time: 30 days, 6 months, 1-5 yearsDescription: Target vessel failure (TVF; cardiovascular death, target vessel myocardial infarction (TV-MI), or target vessel revascularization (TVR))
Measure: Rate of Target Vessel Failure (TVF) Time: 30 days, 6 months, 1-5 yearsDescription: Composite of cardiovascular death, any myocardial infarction and any revascularization
Measure: Composite Rate of cardiovascular death, any myocardial infarction and any revascularization Time: 30 days, 6 months, 1-5 yearsDescription: Ischemia driven target lesion revascularization (ID-TLR)
Measure: Rate of Ischemia driven target lesion revascularization (ID-TLR) Time: 30 days, 6 months, 1-5 yearsDescription: All Target Lesion Revascularization
Measure: Rate of Target Lesion Revascularization (TLR) Time: 30 days, 6 months, 1-5 yearsDescription: All Target Vessel Revascularization
Measure: Rate of Target Vessel Revascularization (TVR) Time: 30 days, 6 months, 1-5 yearsDescription: Ischemia driven target vessel revascularization (ID-TVR)
Measure: Rate of Ischemia driven target vessel revascularization (ID-TVR) Time: 30 days, 6 months, 1-5 yearsDescription: Ischemia driven non target vessel revascularization (ID-NTVR)
Measure: Rate of Ischemia driven non target vessel revascularization (ID-NTVR) Time: 30 days, 6 months, 1-5 yearsDescription: Non target vessel revascularization (NTVR)
Measure: Rate of Non target vessel revascularization (NTVR) Time: 30 days, 6 months, 1-5 yearsDescription: All revascularization
Measure: Rate of All revascularization Time: 30 days, 6 months, 1-5 yearsDescription: All MI, Q-Wave and Non Q-Wave MI, TV-MI, NTV-MI
Measure: Rate of Myocardial Infarction Time: 30 days, 6 months, 1-5 yearsDescription: Cardiovascular Death, All-Cause Death
Measure: Rate of Death Time: 30 days, 6 months, 1-5 yearsDescription: Composite: Cardiovascular death or myocardial infarction
Measure: Composite: Cardiovascular death or myocardial infarction Time: 30 days, 6 months, 1-5 yearsDescription: Composite: All-cause death or myocardial infarction
Measure: Composite: All-cause death or myocardial infarction Time: 30 days, 6 months, 1-5 yearsDescription: Composite: All-cause death, myocardial infarction or target vessel revascularization
Measure: Composite: All-cause death, myocardial infarction or target vessel revascularization Time: 30 days, 6 months, 1-5 yearsDescription: Any stroke (collected at 1 year and 5 years only)
Measure: Rate of any stroke Time: 1 year and 5 yearsDescription: Anginal Status by Seattle Angina Questionnaire-7 (SAQ-7)
Measure: Anginal Status Time: 30 days and 1 yearDescription: Composite: Probable or definite stent thrombosis Probable Stent Thrombosis Definite Stent Thrombosis
Measure: Rate of Stent Thrombosis Time: 30 days, 6 months, 1-5 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports